Abstract 4517: Plasma and tumor pharmacokinetics of IV LMP744, a novel indenoisoquinoline topoisomerase I inhibitor, in a canine phase I study

Conclusion: The plasma pharmacokinetics of LMP744 in dogs display triphasic behavior, a relatively high total body clearance at 57.5 L/h/m2, and a terminal half-life of 183 h. The favorable biodistribution to tumor may be a valuable distinction to consider in the translation of this novel indenoisoquinoline to the clinic.Support: N01-CM-2011-00015, N01-CM-42202 and P30-CA-47904Note: This abstract was not presented at the meeting.Citation Format: Julie L. Eiseman, Julianne Holleran, David L. McCormick, Miguel Muzzio, Joseph M. Covey, Chand Khanna, Christina Mazcko, Yves Pommier, Melissa Paolini, Amy Leblanc, Jenna H. Burton, James H. Doroshow, Joseph E. Tomaszewski, Jan H. Beumer. Plasma and tumor pharmacokinetics of IV LMP744, a novel indenoisoquinoline topoisomerase I inhibitor, in a canine phase I study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4517. doi:10.1158/1538-7445.AM2015-4517

Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Eiseman, J. L., Holleran, J., McCormick, D. L., Muzzio, M., Covey, J. M., Khanna, C., Mazcko, C., Pommier, Y., Paolini, M., Leblanc, A., Burton, J. H., Doroshow, J. H., Tomaszewski, J. E., Beumer, J. H. Tags: Experimental and Molecular Therapeutics Source Type: research